X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6878) 6878
Book Review (707) 707
Newsletter (604) 604
Publication (431) 431
Newspaper Article (42) 42
Magazine Article (29) 29
Conference Proceeding (24) 24
Trade Publication Article (10) 10
Dissertation (5) 5
Book Chapter (3) 3
Paper (3) 3
Book / eBook (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
simvastatin (5681) 5681
index medicus (5462) 5462
humans (4146) 4146
male (3398) 3398
female (2600) 2600
statins (2420) 2420
middle aged (2039) 2039
animals (1802) 1802
cholesterol (1565) 1565
pharmacology & pharmacy (1531) 1531
aged (1527) 1527
simvastatin - administration & dosage (1525) 1525
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (1309) 1309
adult (1243) 1243
atorvastatin (1236) 1236
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (1173) 1173
simvastatin - therapeutic use (1158) 1158
antilipemic agents (1117) 1117
simvastatin - pharmacology (1090) 1090
rats (973) 973
research (961) 961
treatment outcome (957) 957
cardiac & cardiovascular systems (951) 951
pravastatin (924) 924
hypercholesterolemia (870) 870
hydroxymethylglutaryl-coa reductase inhibitors - pharmacology (862) 862
abridged index medicus (829) 829
dosage and administration (829) 829
risk factors (793) 793
drug therapy (785) 785
cholesterol, ldl - blood (784) 784
hypercholesterolemia - drug therapy (780) 780
lipids (712) 712
drug therapy, combination (704) 704
atorvastatin calcium (700) 700
anticholesteremic agents - administration & dosage (684) 684
anticholesteremic agents - therapeutic use (671) 671
analysis (664) 664
dose-response relationship, drug (660) 660
atherosclerosis (612) 612
mice (586) 586
care and treatment (582) 582
cholesterol - blood (576) 576
prevention (574) 574
therapy (568) 568
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (558) 558
lovastatin (548) 548
medicine, general & internal (541) 541
ezetimibe (540) 540
risk (540) 540
coronary-heart-disease (517) 517
peripheral vascular disease (509) 509
inflammation (506) 506
double-blind method (500) 500
statin (489) 489
drugs (488) 488
time factors (479) 479
simvastatin - adverse effects (459) 459
cardiovascular disease (454) 454
coa reductase inhibitors (453) 453
health aspects (441) 441
drug interactions (436) 436
disease (429) 429
low density lipoproteins (422) 422
triglycerides - blood (399) 399
heptanoic acids - administration & dosage (394) 394
expression (393) 393
pyrroles - administration & dosage (393) 393
lipids - blood (392) 392
disease models, animal (388) 388
efficacy (388) 388
cardiovascular diseases (385) 385
mortality (375) 375
rosuvastatin (367) 367
medicine & public health (365) 365
rats, sprague-dawley (358) 358
in-vitro (357) 357
hypercholesterolemia - blood (356) 356
safety (353) 353
aged, 80 and over (347) 347
heptanoic acids - therapeutic use (346) 346
complications and side effects (344) 344
pyrroles - therapeutic use (343) 343
cardiovascular (342) 342
rats, wistar (341) 341
c-reactive protein (333) 333
clinical trials (332) 332
medicine, research & experimental (330) 330
metabolism (329) 329
oxidative stress (328) 328
cholesterol, hdl - blood (323) 323
hypolipidemic agents - therapeutic use (320) 320
anticholesteremic agents - pharmacology (317) 317
studies (315) 315
anticholesteremic agents - adverse effects (314) 314
hyperlipidemias - drug therapy (314) 314
cardiovascular-disease (311) 311
myocardial-infarction (308) 308
cardiovascular agents (306) 306
medical research (306) 306
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7304) 7304
German (52) 52
Russian (48) 48
Chinese (26) 26
Spanish (23) 23
Swedish (19) 19
French (14) 14
Italian (13) 13
Portuguese (11) 11
Japanese (10) 10
Danish (8) 8
Hungarian (8) 8
Norwegian (8) 8
Polish (6) 6
Czech (5) 5
Turkish (4) 4
Dutch (2) 2
Croatian (1) 1
Finnish (1) 1
Hebrew (1) 1
Korean (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


British Journal of Clinical Pharmacology, ISSN 0306-5251, 08/2012, Volume 74, Issue 2, pp. 336 - 345
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • In healthy subjects, GSK2248761 was shown to be safe and well tolerated with single doses up to 1200 mg once daily... 
NNRTI | HIV‐1 infection | antiretroviral therapy | drug‐drug interaction | HIV-1 infection | Drug-drug interaction | Antiretroviral therapy | PHARMACOKINETICS | TOLERABILITY | PHARMACOLOGY & PHARMACY | ATAZANAVIR | SIMVASTATIN | drug-drug interaction | PROTEASE INHIBITORS | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Darunavir | Ethinyl Estradiol - pharmacokinetics | Humans | Pyrrolidinones - pharmacokinetics | Male | Fluorobenzenes - administration & dosage | Indoles - administration & dosage | Lopinavir - pharmacokinetics | Anti-HIV Agents - administration & dosage | Pyrrolidinones - administration & dosage | Tenofovir | Deoxycytidine - pharmacokinetics | Drug Interactions | Pyrroles - administration & dosage | Contraceptives, Oral - administration & dosage | Patient Safety | Atazanavir Sulfate | Contraceptives, Oral - pharmacokinetics | Phosphinic Acids - administration & dosage | Raltegravir Potassium | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Risk Assessment | Simvastatin - administration & dosage | Deoxycytidine - administration & dosage | Phosphinic Acids - pharmacokinetics | Rosuvastatin Calcium | Adenine - pharmacokinetics | Sulfonamides - pharmacokinetics | Cross-Over Studies | Cytochrome P-450 CYP3A - metabolism | Atorvastatin | Cytochrome P-450 CYP2D6 - metabolism | Least-Squares Analysis | Lopinavir - administration & dosage | Pyrimidines - pharmacokinetics | Oligopeptides - administration & dosage | Deoxycytidine - analogs & derivatives | Sulfonamides - administration & dosage | Cytochrome P-450 CYP2D6 Inhibitors | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Heptanoic Acids - pharmacokinetics | Pyridines - pharmacokinetics | Reverse Transcriptase Inhibitors - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Reverse Transcriptase Inhibitors - pharmacokinetics | Heptanoic Acids - administration & dosage | Female | Ethinyl Estradiol - administration & dosage | Androstenes - pharmacokinetics | Double-Blind Method | Ritonavir - administration & dosage | Pyrimidines - administration & dosage | Oligopeptides - pharmacokinetics | Linear Models | Simvastatin - pharmacokinetics | Androstenes - administration & dosage | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Organophosphonates - administration & dosage | Cytochrome P-450 CYP3A Inhibitors | Ritonavir - pharmacokinetics | Anti-HIV Agents - pharmacokinetics | Indoles - pharmacokinetics | Drug Combinations | Urine | Simvastatin | Drug interactions | Cytochrome P-450 | HIV (Viruses) | Complications and side effects | Analysis | Electrocardiogram | Electrocardiography | DNA polymerases | Ethinyl estradiol | Dosage and administration | Index Medicus | EKG | Antiviral agents | Urinalysis | Ritonavir | tenofovir | Cytochrome P450 | Lopinavir | ethinylestradiol | Blood | Infection | non-nucleoside reverse transcriptase inhibitors | Antiviral activity | Drug interaction | Probes | CYP2D6 protein
Journal Article
European Journal of Preventive Cardiology, ISSN 2047-4873, 7/2015, Volume 22, Issue 7, pp. 920 - 930
Background Most individuals at high cardiovascular disease (CVD) risk worldwide do not receive any or optimal preventive drugs. We aimed to determine whether... 
blood pressure | Cardiovascular disease | cholesterol | polypill | adherence | prevention | NON-INDIGENOUS PEOPLE | DRUG-THERAPY | DESIGN | CARDIAC & CARDIOVASCULAR SYSTEMS | MANAGEMENT | RATIONALE | MEDICATION NONADHERENCE | IMPACT | GAP | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Hyperlipidemias - blood | Prospective Studies | Tablets | Cardiovascular Diseases - prevention & control | Cholesterol - blood | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Hypertension - drug therapy | Male | Aspirin - administration & dosage | Hyperlipidemias - diagnosis | Polypharmacy | Time Factors | Platelet Aggregation Inhibitors - administration & dosage | General Practice | Sodium Chloride Symporter Inhibitors - administration & dosage | Cardiovascular Diseases - blood | Female | Adrenergic beta-1 Receptor Antagonists - administration & dosage | Blood Pressure - drug effects | Atenolol - administration & dosage | Hypertension - diagnosis | Hyperlipidemias - complications | Cardiovascular Diseases - diagnosis | Lisinopril - administration & dosage | Cardiovascular Diseases - etiology | Cardiovascular Diseases - physiopathology | Administration, Oral | Simvastatin - administration & dosage | Hyperlipidemias - drug therapy | Risk Factors | Drugs, Generic - administration & dosage | Treatment Outcome | Hydrochlorothiazide - administration & dosage | Biomarkers - blood | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Hypertension - physiopathology | Primary Prevention - methods | Hypertension - complications | Aged | Australia | Drug Combinations | Index Medicus
Journal Article
The American Journal of Cardiology, ISSN 0002-9149, 2004, Volume 94, Issue 9, pp. 1140 - 1146
Three-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors (statins) are first-line treatments for hypercholesterolemia. Although exceedingly well... 
CLARITHROMYCIN | INDUCED RHABDOMYOLYSIS | LOVASTATIN | CARDIAC & CARDIOVASCULAR SYSTEMS | CONCOMITANT USE | ERYTHROMYCIN | FATAL RHABDOMYOLYSIS | ITRACONAZOLE | ROSUVASTATIN | DRUG-INTERACTION | CYCLOSPORINE | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Pyrroles - pharmacokinetics | Cytochrome P-450 Enzyme Inhibitors | Cytochrome P-450 Enzyme System - administration & dosage | Area Under Curve | Heptanoic Acids - pharmacokinetics | Humans | Middle Aged | Mibefradil - pharmacokinetics | Male | Protein Synthesis Inhibitors - administration & dosage | Verapamil - administration & dosage | Dose-Response Relationship, Drug | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Antiprotozoal Agents - pharmacokinetics | Drug Interactions | Itraconazole - pharmacokinetics | Pyrroles - administration & dosage | Clarithromycin - pharmacokinetics | Mibefradil - administration & dosage | Clarithromycin - administration & dosage | Heptanoic Acids - administration & dosage | Adult | Female | Itraconazole - administration & dosage | Drug Therapy, Combination | Double-Blind Method | Simvastatin - administration & dosage | Verapamil - pharmacokinetics | Biomarkers - blood | Simvastatin - pharmacokinetics | Protein Synthesis Inhibitors - pharmacokinetics | Atorvastatin Calcium | Anticholesteremic Agents - pharmacokinetics | Pravastatin - administration & dosage | Anticholesteremic Agents - administration & dosage | Adolescent | Antiprotozoal Agents - administration & dosage | Calcium Channel Blockers - administration & dosage | Creatine Kinase - drug effects | Calcium Channel Blockers - pharmacokinetics | Pravastatin - pharmacokinetics | Index Medicus | Abridged Index Medicus
Journal Article
JAMA, ISSN 0098-7484, 05/2014, Volume 311, Issue 18, pp. 1870 - 1882
Journal Article
BMJ : British Medical Journal, ISSN 0959-8138, 5/2013, Volume 346, Issue 7911, pp. 14 - 14
Objective To examine the risk of new onset diabetes among patients treated with different HMG-CoA reductase inhibitors (statins).Design Population based cohort... 
RESEARCH | Secondary prevention | Depopulation | Population growth | Diabetes | Older adults | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | THERAPY | EVENTS | CHOLESTEROL | CORONARY | DISEASE | PREVENTION | RANDOMIZED CONTROLLED-TRIAL | MELLITUS | ATORVASTATIN | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Simvastatin - adverse effects | Cardiovascular Diseases - prevention & control | Humans | Male | Fluorobenzenes - administration & dosage | Heptanoic Acids - adverse effects | Diabetes Mellitus, Type 2 - epidemiology | Incidence | Dose-Response Relationship, Drug | Pyrroles - administration & dosage | Cardiovascular Diseases - epidemiology | Heptanoic Acids - administration & dosage | Pravastatin - adverse effects | Pyrroles - adverse effects | Diabetes Mellitus, Type 2 - etiology | Female | Retrospective Studies | Odds Ratio | Dyslipidemias - drug therapy | Pyrimidines - administration & dosage | Simvastatin - administration & dosage | Proportional Hazards Models | Rosuvastatin Calcium | Treatment Outcome | Atorvastatin Calcium | Dyslipidemias - epidemiology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Pravastatin - administration & dosage | Ontario - epidemiology | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Aged | Fluorobenzenes - adverse effects | Diabetes Mellitus, Type 2 - chemically induced | Population Surveillance | Sulfonamides - administration & dosage | Cohort Studies | Inhibitor drugs | Risk assessment | Statins | Clinical outcomes | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
European Journal of Pharmaceutics and Biopharmaceutics, ISSN 0939-6411, 02/2014, Volume 86, Issue 2, pp. 133 - 144
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 2011, Volume 103, Issue 11, pp. 885 - 892
Journal Article
Journal of Bone and Mineral Research, ISSN 0884-0431, 05/2012, Volume 27, Issue 5, pp. 1118 - 1131
Several reports have shown the therapeutic effect of statins on bone formation and neovascularization. However, the effect of the systemic administration of... 
OSTEOGENESIS | SIMVASTATIN | GELATIN‐HYDROGEL | FRACTURE HEALING | ENDOTHELIAL PROGENITOR CELL | GELATIN-HYDROGEL | CONTROLLED-TRIAL | STEM-CELLS | COA REDUCTASE INHIBITORS | ANGIOGENESIS | ENDOTHELIAL PROGENITOR CELLS | IN-VITRO | REPAIR | STATIN THERAPY | ENDOCRINOLOGY & METABOLISM | BONE REGENERATION | NEOVASCULARIZATION | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Neovascularization, Physiologic - drug effects | Adjuvants, Pharmaceutic - pharmacology | Femur - blood supply | Gelatin - pharmacology | Male | Femur - diagnostic imaging | Simvastatin - pharmacology | Drug Delivery Systems | Fracture Healing - drug effects | Bone Marrow Transplantation | Female | Hydrogel, Polyethylene Glycol Dimethacrylate - pharmacology | Simvastatin - administration & dosage | Mice, Inbred C57BL | Osteoblasts - drug effects | Osteogenesis - drug effects | Cells, Cultured | Rats | Femur - drug effects | Radiography | Cell Movement - drug effects | Animals | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Mice | Administration, Topical | Index Medicus | Femur | Biodegradability | Periosteum | Liver | Simvastatin | Drug delivery | Nonunion | hydrogels | Bone healing | Metabolism | Angiogenesis | Side effects | Fractures | Gelatin | statins | vascularization | Growth factors | Osteogenesis
Journal Article
JAMA, ISSN 0098-7484, 09/2013, Volume 310, Issue 9, pp. 918 - 929
Journal Article